851 results on '"Cerchietti, Leandro"'
Search Results
102. Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies
103. A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
104. Morphine Versus Midazolam as Upfront Therapy to Control Dyspnea Perception in Cancer Patients While Its Underlying Cause Is Sought or Treated
105. The eukaryotic translation initiation factor eIF4E reprogrammes the splicing machinery and drives alternative splicing
106. A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments
107. High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study
108. Phase I Study of Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
109. The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases
110. S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements
111. Aging-Associated Epigenetic Reprogramming Alters the Germinal Center Reaction and Targets Pathways Related to Lymphomagenesis
112. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL
113. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
114. Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
115. Abstract LB014: Translational activation of ATF4 through mitochondrial anaplerotic metabolic pathways is required for DLBCL growth and survival
116. Oncogenic HSP90 facilitates metabolic alterations in aggressive B-cell lymphomas
117. Qpctl Inhibition, By Targeting the Inflammatory Tumor Microenvironment, Constitutes a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma
118. Remodeling of the Immune Microenvironment By Oncogenic MYD88 Dictates Immunotherapy Responses across Indolent and Aggressive B-Cell Lymphomas
119. Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer
120. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
121. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas
122. Endothelial cell–leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities
123. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
124. Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphoma
125. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases
126. Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
127. Variational autoencoders learn universal latent representations of metabolomics data
128. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells
129. Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma
130. Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?
131. Variational autoencoders learn transferrable representations of metabolomics data.
132. Midazolam as Adjunct Therapy to Morphine in the Alleviation of Severe Dyspnea Perception in Patients with Advanced Cancer
133. List of contributors
134. XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells
135. A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas
136. Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)
137. Abstract IA05: Microenvironmental signatures reveal biologic and clinical subtypes of diffuse large B-cell lymphoma
138. The eukaryotic translation initiation factor eIF4E elevates steady-state m 7 G capping of coding and noncoding transcripts
139. Abstract 1288: BCL6 drives an oncogenic transcriptional and epigenetic program in NSCLC whose inhibition results in antineoplastic activity in vivo
140. A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries
141. HSP90 facilitates oncogenic alterations of metabolism in B-cell lymphomas
142. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer
143. SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas – Aiming to improve therapy, outcomes, and...
144. The epichaperome is an integrated chaperome network that facilitates tumour survival
145. Methods and Tools for MeRIP-Seq and Nanopore Detection of m6A(m) Changes
146. Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study
147. Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma
148. Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study
149. Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling
150. Limits in the detection of m6A changes using MeRIP/m6A-seq
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.